Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

DyeVert™ Plus Contrast Reduction System Multicenter Observational Study

NCT03715452 · View on ClinicalTrials.gov ↗

Study Summary

This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and permit real-time contrast media volume monitoring.

Conditions Studied

Interventions

  • DEVICE DyeVert Plus Contrast Reduction System

Study Locations (8)

California

  • Harbor UCLA Medical Center — Torrance

Georgia

  • Atlanta VA Medical Center, Emory University School of Medicine — Atlanta

Illinois

  • University of Chicago Medical Center — Chicago

Michigan

  • William Beaumont Hospital — Royal Oak

Mississippi

  • North Mississippi Medical Center — Tupelo

Missouri

  • Washington University School of Medicine — St Louis

North Carolina

  • WakeMed Heart and Vascular — Raleigh

Ohio

  • Christ Hospital, Heart and Vascular Center, Lindner Research Center — Cincinnati

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2017-07-01
Est. Completion 2018-03-30

Sponsor

Osprey Medical

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03715452

The ClinicalTrials.gov registry entry for NCT03715452 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Osprey Medical, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention — of which DyeVert Plus Contrast Reduction System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03715452 reports 8 study locations spanning 8 distinct geographic areas — top geographies include California, Georgia, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03715452 about?

NCT03715452 is a clinical study titled "DyeVert™ Plus Contrast Reduction System Multicenter Observational Study". This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and permit real-time contrast media volume monitoring.

What is the current status of trial NCT03715452?

This trial is currently completed. The enrollment target is 114 participants. The study started on 2017-07-01. Estimated completion is 2018-03-30.

What conditions does trial NCT03715452 study?

This clinical trial studies the following conditions: Chronic Kidney Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03715452?

The interventions under investigation include: DyeVert Plus Contrast Reduction System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03715452?

This trial is sponsored by Osprey Medical, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03715452 being conducted?

This trial has 8 study locations across California, Georgia, Illinois, Michigan, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial